immunotherapy

Department
Biomarker Tied to Immunotherapy Response in Melanoma
09/30/2016
JCP Editors
Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy...
Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy...
...
09/30/2016
Journal of Clinical Pathways
Department
PD-L1 Tests for NSCLC Differ in Effectiveness
09/28/2016
JCP Editors
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A...
09/28/2016
Journal of Clinical Pathways
Research in Review
Drug Combination Does Not Benefit Patients With Colorectal Cancer
09/26/2016
JCP Editors
There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...
There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...
There...
09/26/2016
Journal of Clinical Pathways
Research in Review
PD-1 Inhibitor-Related Pneumonitis Most Common in NSCLC
09/23/2016
JCP Editors
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
...
09/23/2016
Journal of Clinical Pathways
Department
Integrating Precision Medicine Into Chronic Lymphocytic Leukemia Pathways
09/21/2016
JCP Editors
“It is time to rethink how we treat chronic lymphocytic leukemia (CLL),” said Chadi Nabhan, MD, MBA, FACP, Cardinal Health Specialty Solutions (Chicago, IL) during a session at the Clinical Pathways Congress, where...
“It is time to rethink how we treat chronic lymphocytic leukemia (CLL),” said Chadi Nabhan, MD, MBA, FACP, Cardinal Health Specialty Solutions (Chicago, IL) during a session at the Clinical Pathways Congress, where...
“It is...
09/21/2016
Journal of Clinical Pathways
Department
The End of Clinical Pathways?
09/19/2016
JCP Editors
In a presentation at the inaugural Clinical Pathways Congress, Michael Kolodziej, MD, national medical director, Managed Care Strategy, Flatiron Health, argued that clinical pathways as we know them will cease to...
In a presentation at the inaugural Clinical Pathways Congress, Michael Kolodziej, MD, national medical director, Managed Care Strategy, Flatiron Health, argued that clinical pathways as we know them will cease to...
In a...
09/19/2016
Journal of Clinical Pathways
Research in Review
Dose Adjustment Reduces AEs Without Impacting Efficacy in NSCLC
09/14/2016
JCP Editors
Tolerability-guided dose adjustment is an effective measure to reduce afatinib (Giotrif)-related adverse events (AEs) without affecting therapeutic efficacy in patients with non–small cell lung cancer (NSCLC),...
Tolerability-guided dose adjustment is an effective measure to reduce afatinib (Giotrif)-related adverse events (AEs) without affecting therapeutic efficacy in patients with non–small cell lung cancer (NSCLC),...
...
09/14/2016
Journal of Clinical Pathways
Research in Review
Esophageal Cancer Actually 3 Distinct Diseases
09/09/2016
JCP Editors
A study published in Nature Genetics claims that esophageal cancer may in fact be 3 distinct diseases, which could pave the way for new methods of diagnosis and spur the development of targeted treatment...
A study published in Nature Genetics claims that esophageal cancer may in fact be 3 distinct diseases, which could pave the way for new methods of diagnosis and spur the development of targeted treatment...
A...
09/09/2016
Journal of Clinical Pathways
Research in Review
Treatment Combination Improves NSCLC Survival and Response
08/12/2016
JCP Editors
East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...
East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...
East...
08/12/2016
Journal of Clinical Pathways
Research in Review
Immunotherapy Plus Chemotherapy Does not Improve SCLC Outcomes
08/05/2016
JCP Editors
The addition of ipilimumab to etoposide and a platinum agent failed to demonstrate improved survival in patients with extensive-stage small-cell lung cancer when compared with chemotherapy alone, a study published in...
The addition of ipilimumab to etoposide and a platinum agent failed to demonstrate improved survival in patients with extensive-stage small-cell lung cancer when compared with chemotherapy alone, a study published in...
The...
08/05/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use